Lv1
34 积分 2022-10-28 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Site-specific tethering nanobodies on recombinant adeno-associated virus vectors for retargeted gene therapy
4个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
8个月前
已完结
Linking tumour angiogenesis and tumour immunity
8个月前
已完结
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
8个月前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
9个月前
已完结
皖公网安备34019202002308
